 |
 |
1: Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline Mech Ageing Dev. 2000 Jul 31;116(2-3):181-91. PMID: 10996018 2: Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MB. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 2000 Jun 23;67(5):577-85. PMID: 10993123 3: Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999;106(7-8):593-606. PMID: 10907720 4: Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev. 1999 Nov;111(2-3):189-200. PMID: 10656536 5: Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res. 1999 Nov 1;58(3):456-63. PMID: 10518120 6: Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80:495-9. No abstract available. PMID: 10410762 7: Lamensdorf I, Porat S, Simantov R, Finberg JP. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br J Pharmacol. 1999 Feb;126(4):997-1002. PMID: 10193780 8: Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999 Feb 5;366(2-3):127-35. PMID: 10082192 9: Speiser Z, Katzir O, Rehavi M, Zabarski T, Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav. 1998 Jun;60(2):387-93. PMID: 9632221 10: Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, Finberg J. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998;52:301-5. PMID: 9564630 11: Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl. 1998;52:287-300. PMID: 9564629 12: Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl. 1998;52:279-85. PMID: 9564628 13: Gotz ME, Breithaupt W, Sautter J, Kupsch A, Schwarz J, Oertel WH, Youdim MB, Riederer P, Gerlach M. Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm Suppl. 1998;52:271-8. PMID: 9564627 14: Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 1998 Mar 9;9(4):703-7. PMID: 9559942 15: Lamensdorf I, Youdim MB, Finberg JP. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem. 1996 Oct;67(4):1532-9. PMID: 8858937 16: Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996;48:95-101. PMID: 8988465 17: Finberg JP, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J Neurochem. 1995 Sep;65(3):1213-20. PMID: 7643100 18: Youngster SK, Saari WS, Heikkila RE. 1-Methyl-4-cyclohexyl-1,2,3,6-tetrahydropyridine (MCTP): an alicyclic MPTP-like neurotoxin. Neurosci Lett. 1987 Aug 18;79(1-2):151-6. PMID: 3499585 19: Youdim MB, Finberg JP. MAO type B inhibitors as adjunct to L-dopa therapy. Adv Neurol. 1987;45:127-36. No abstract available. PMID: 3103383 20: Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem. 1986 May;46(5):1359-65. PMID: 2420928 21: Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985 Oct 22;116(3):313-7. PMID: 3935467 22: Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B. J Neurochem. 1985 Oct;45(4):1049-54. PMID: 3928814 23: Finberg JP, Youdim MB. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br J Pharmacol. 1985 Jun;85(2):541-6. PMID: 3928010 24: Finberg JP, Tenne M, Youdim MB. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981 May;73(1):65-74. PMID: 6793119 http://www.ncbi.nlm.nih.gov/PubMed/ janet paterson, an akinetic rigid subtype parkie 53 now / 44 dx cd / 43 onset cd / 41 dx pd / 37 onset pd TEL: 613 256 8340 SMAIL: PO Box 171 Almonte Ontario K0A 1A0 Canada EMAIL: [log in to unmask] URL: http://www.geocities.com/janet313/